{
    "clinical_study": {
        "@rank": "121196", 
        "arm_group": {
            "arm_group_label": "KHK7580", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after\n      single administration of KHK7580 for secondary hyperparathyroidism in patients receiving\n      peritoneal dialysis."
        }, 
        "brief_title": "Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Secondary Hyperparathyroidism", 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Secondary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Stable chronic renal disease patients receiving peritoneal dialysis for at least 16\n             weeks prior to the screening\n\n          -  intact parathyroid hormone value \u2265 240 pg/mL at the screening\n\n          -  Corrected serum calcium \u2265 8.4 mg/dL at the screening\n\n        Exclusion Criteria:\n\n          -  Patients with primary hyperparathyroidism\n\n          -  Patients who received cinacalcet within 2 weeks prior to the screening\n\n          -  Patients who began to take or changed the dose/dosing regimen of active vitamin D/its\n             analogs, phosphate binders and/or calcium containing compounds within 2 weeks prior\n             to the screening\n\n          -  Patients who underwent parathyroidectomy and/or parathyroid intervention\n\n          -  Patients with uncontrolled hypertension and/or diabetes\n\n          -  Patients with severe heart disorder\n\n          -  Patients with severe hepatic disease\n\n          -  Patients who take investigational drug in another clinical trial within 12 weeks\n             prior to the screening\n\n          -  Patients who have been judged ineligible to participate in the study by the\n             investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143271", 
            "org_study_id": "7580-004"
        }, 
        "intervention": {
            "arm_group_label": "KHK7580", 
            "description": "Oral administration", 
            "intervention_name": "KHK7580", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "contact": {
                "email": "clinical.info@kyowa-kirin.co.jp", 
                "last_name": "KYOWA HAKKO KIRIN"
            }, 
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }, 
                "name": "Kyowa Hakko Kirin"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-dose Phase 1 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The safety of KHK7580 assessed by number and types of adverse events, laboratory tests, vital signs and electrocardiogram", 
            "measure": "Number and types of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "For 8 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143271"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "intact parathyroid hormone, whole parathyroid hormone, corrected serum calcium, phosphorus, intact fibroblast growth factor 23, ionized calcium, calcitonin", 
            "measure": "Profiles of pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 and 168 hours post-dose"
        }, 
        "source": "Kyowa Hakko Kirin Company, Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Company, Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}